Novartis Pharmaceuticals Canada Inc.
36 meetings with public office holders, Aug 28, 2025 to Jul 22, 2026.
138 meetings on record since 2010, their first on record.
Meetings over time
- Aug 2025: 1 meeting, with Shahad Khalladi
- Sep 2025: 4 meetings, with Yash Nanda, Manuela Tomic, Shahad Khalladi
- Oct 2025: 4 meetings, with Mike Lake, Karim Bardeesy, Marc Miller, Jeremy Patzer
- Nov 2025: 13 meetings, with Marie-Christine Demers, Meron Cheway, Sandenga Yeba, Mahamat Djalal, Jennifer McKelvie
- Dec 2025: 1 meeting, with Marjorie Michel, Sandenga Yeba
- Jan 2026: 0 meetings
- Feb 2026: 2 meetings, with Paul Moen, Manuela Tomic, Jade Mallette, Sandenga Yeba
- Mar 2026: 1 meeting, with Kristina Tesser Derksen
- Apr 2026: 7 meetings, with Ritu Banerjee, Rodrigo Arancibia, Matthew Trnkus, Galen Richardson, Nasser Haidar
- May 2026: 2 meetings, with Shalene Curtis-Micallef, Jocelyne Voisin
- Jun 2026: 0 meetings
- Jul 2026: 1 meeting, with Mark Carney, Marc-André Blanchard
Aug 2025peak 13 in a monthJul 2026
Hover or focus a month to see who was met.
What they lobby about
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal8 met · 11 meetings
Conservative3 met · 3 meetings
Not in Arena's member list22 met · 36 meetings
- Sandenga Yeba
- Manuela Tomic
- Shahad Khalladi
- Galen Richardson
- Mackenzy Metcalfe
- Mahamat Djalal
- Matthew Trnkus
- Nasser Haidar
- Niloo Boroun
- Yash Nanda
- Alexandre Bergeron
- Jade Mallette
- Jibril Hussein
- Jocelyne Voisin
- Marc-André Blanchard
- Marie-Christine Demers
- Meron Cheway
- Paul Moen
- Ritu Banerjee
- Rodrigo Arancibia
- Shalene Curtis-Micallef
- Shawn Boyle
Health Canada (HC) (14) · House of Commons (12) · Innovation, Science and Economic Development Canada (ISED) (9) · Finance Canada (FIN) (4) · Prime Minister's Office (PMO) (4) · Privy Council Office (PCO) (2)
In their own words
- Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
- Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.
- Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.